GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » EPS (Diluted)

ACTU (Actuate Therapeutics) EPS (Diluted) : $-1.76 (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics EPS (Diluted)?

Actuate Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.76.

Actuate Therapeutics's EPS (Basic) for the three months ended in Dec. 2024 was $-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.76.

Actuate Therapeutics's EPS without NRI for the three months ended in Dec. 2024 was $-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.80.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Actuate Therapeutics EPS (Diluted) Historical Data

The historical data trend for Actuate Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics EPS (Diluted) Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
EPS (Diluted)
-1.34 -1.30 -3.26

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only -0.40 -0.54 -0.34 -0.55 -0.33

Competitive Comparison of Actuate Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Actuate Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actuate Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's PE Ratio falls into.


;
;

Actuate Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Actuate Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as

Diluted EPS (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-27.285-0)/8.373
=-3.26

Actuate Therapeutics's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as

Diluted EPS (Q: Dec. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.446-0)/19.532
=-0.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actuate Therapeutics  (NAS:ACTU) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Actuate Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Actuate Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.